References
- Wong RW, Jumper JM, McDonald HR, et al. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol 2013;97:545–552.
- Gnann JW. Varicella-zoster virus: atypical presentations, and unusual complications. J Infect Dis 2002;186:S91–S98.
- Kawaguchi T, Spencer DB, Mochizuki M. Therapy for acute retinal necrosis. Semin Ophthalmol 2008;23:285–290.
- Tam PM, Hooper CY, Lightman S. Antiviral selection in the management of acute retinal necrosis. Clin Ophthalmol 2010;4:11–20.
- MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004;53:899–901.
- Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754–752.
- Valtrex [package insert]. Research Triangle Park, NC: GlaxoSmithKlein; 2008.
- Taylor SR, Hamilton R, Hooper CY, et al. Valacyclovir in the treatment of acute retinal necrosis. BMC Ophthalmol 2012;12:48.
- Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology 2007;114:307–312.
- Aslanides IM, De Souza S, Wong DT, et al. Oral valacyclovir in the treatment of acute retinal necrosis syndrome. Retina 2002;22:352–354.
- Emerson GG, Smith JR, Wilson DJ, Rosenbaum JT, Flaxel CJ. Primary treatment of acute retinal necrosis with oral antiviral therapy. Ophthalmology 2006;113:2259–2261.
- Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982;73:186–192.
- Vezina HE, Balfour HH, Weller DR, et al. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein–Barr virus infectious mononucleosis. J Clin Pharmacol 2010;50:734–742.
- de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983; Suppl B:29–37.
- Huynh TH, Johnson MW, Comer GM, et al. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol 2008;145:682–686.
- Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004;38:1907–1915.
- Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980;18:443–447.
- Steingrimsdottir H, Gruber A, Palm C, et al. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 2000;44:207–209.
- Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595–605.